Breaking News

Algorithme Pharma, HMR in Patient Access Pact

By Kristin Brooks | December 11, 2013

To offer patient access in key therapeutic areas

Algorithme Pharma has partnered with Hôpital Maisonneuve-Rosemont (HMR) to offer sponsors increased patient access in key therapeutic areas, including hematology, oncology, nephrology, ophthalmology and metabolic diseases. The HMR clinical research team has more than 60 clinicians and is supported by approximately 75 employees. 
 
“As sponsors look to obtain more information on their lead drug earlier in development, the need to include patient populations in early stage clinical trials continues to increase. Partnering with research teams who have expertise in key therapeutic areas advances our goal of providing a full spectrum of Phase I/IIa clinical research services to our diverse client base,” said Dr. Marc Lefebvre, vice president Scientific & Regulatory Affairs, Algorithme Pharma.
 
Dr. Pierre Dubé, associate director, Clinical Research Division, Hôpital Maisonneuve-Rosemont, added, “In this partnership between private and academic organizations, our clinical investigators and researchers will be able to leverage Algorithme Pharma’s immense wealth of knowledge. For HMR and its Research Centre, this kind of collaboration is part of our strategic objectives which aim to continually deliver innovative treatments to our patients.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important